retail news in context, analysis with attitude

• Safeway announced that it is in the process of dissolving its relationship with Theranos, a startup company that it contracted with for $350 million, with the goal of building medical clinics in 800 of its stores.

The Wall Street Journal writes that "the tests never began, the clinics are now used largely for flu shots and travel-related vaccines ... Current and former Safeway executives said Theranos missed deadlines for the blood-testing rollout. They also said several Safeway executives questioned the accuracy of results Theranos gave to Safeway employees tested at a clinic in the supermarket chain’s headquarters in Pleasanton, Calif."

Safeway was the exclusive supermarket company with which Theranos was doing business, but the startup also had a deal with Walgreens - which also has stopped building new Theranos-run clinics until questions about its technology have been resolved.


• The New York Times this morning reports that Anheuser-Busch InBev has completed its deal to acquire SABMiller for about $105 billion. The deal, the story notes, "would create a behemoth in the beer industry with annual revenue of about $64 billion and would give Anheuser-Busch InBev more exposure in faster-growing emerging markets, particularly in Africa and Latin America.

"Hoping to gain regulatory approval for the merger, SABMiller said on Wednesday that it would sell its 58 percent stake in MillerCoors in the United States to its joint venture partner Molson Coors Brewing Company for about $12 billion. That deal is conditioned on the Anheuser-Busch InBev transaction closing and includes the rights to the Miller brand globally."
KC's View: